Design of the β3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Garcia-Lunar, Inés
- dc.contributor.author Solé-González, Eduard
- dc.contributor.author García-Álvarez, Ana
- dc.date.accessioned 2020-09-07T06:58:54Z
- dc.date.available 2020-09-07T06:58:54Z
- dc.date.issued 2020
- dc.description.abstract Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).
- dc.format.mimetype application/pdf
- dc.identifier.citation Garcia-Lunar I, Blanco I, Fernández-Friera L, Prat-Gonzàlez S, Jordà P, Sánchez J. et al. Design of the β3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial. JACC Basic Transl Sci. 2020 Mar 11; 5(4):317-327. DOI: 10.1016/j.jacbts.2020.01.009
- dc.identifier.doi http://dx.doi.org/10.1016/j.jacbts.2020.01.009
- dc.identifier.issn 2452-302X
- dc.identifier.uri http://hdl.handle.net/10230/45260
- dc.language.iso eng
- dc.publisher Elsevier
- dc.rights Copyright © 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword CCT
- dc.subject.keyword Cardiac computed tomography
- dc.subject.keyword CMR
- dc.subject.keyword Cardiac magnetic resonance
- dc.subject.keyword CpcPH
- dc.subject.keyword Combined pre - and post - capillary pulmonary hypertension
- dc.subject.keyword ECG
- dc.subject.keyword Electrocardiography
- dc.subject.keyword Heart failure
- dc.subject.keyword Intention to treat
- dc.subject.keyword Isolated post-capillary pulmonary hypertension
- dc.subject.keyword Left heart disease
- dc.subject.keyword Left ventricular
- dc.subject.keyword Left ventricular ejection fraction
- dc.subject.keyword N-terminal prohormone of brain natriuretic peptide
- dc.subject.keyword New York Heart Association
- dc.subject.keyword Pulmonary artery pressure
- dc.subject.keyword Pulmonary hypertension
- dc.subject.keyword Per protocol
- dc.subject.keyword Pulmonary vascular resistance
- dc.subject.keyword Right ventricle
- dc.subject.keyword Adrenoreceptors
- dc.subject.keyword Cyclic guanosine monophosphate
- dc.subject.keyword Imaging
- dc.subject.keyword Pulmonary hypertension
- dc.subject.keyword Treatment
- dc.subject.keyword Beta-3 adrenoreceptor
- dc.title Design of the β3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion